

Gincy George

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7470809/publications.pdf>

Version: 2024-02-01

18
papers

585
citations

1039406

9
h-index

940134

16
g-index

19
all docs

19
docs citations

19
times ranked

1423
citing authors

#	ARTICLE	IF	CITATIONS
1	Qualitative Analysis of Interviews and Focus Groups Exploring Factors Contributing to Adherence to GnRH Agonists in Men with Prostate Cancer. <i>Seminars in Oncology Nursing</i> , 2022, 38, 151236.	0.7	2
2	Depression, anxiety, and suicidality in patients with prostate cancer: a systematic review and meta-analysis of observational studies. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 281-289.	2.0	50
3	Risk of cardiovascular disease following gonadotropin-releasing hormone agonists vs antagonists in prostate cancer: Real-world evidence from five databases. <i>International Journal of Cancer</i> , 2021, 148, 2203-2211.	2.3	19
4	Risk of cardiovascular events in men on abiraterone or enzalutamide combined with GnRH agonists: nation-wide, population-based cohort study in Sweden. <i>Acta Oncologica</i> , 2021, 60, 459-465.	0.8	7
5	Erectile Function Following Surgery for Benign Prostatic Obstruction: A Systematic Review and Network Meta-analysis of Randomised Controlled Trials. <i>European Urology</i> , 2021, 80, 174-187.	0.9	5
6	The incidence and prevalence of upper tract urothelial carcinoma: a systematic review. <i>BMC Urology</i> , 2021, 21, 110.	0.6	28
7	Risk of COVID-19 death in cancer patients: an analysis from Guy's Cancer Centre and King's College Hospital in London. <i>British Journal of Cancer</i> , 2021, 125, 939-947.	2.9	41
8	Real-world outcomes associated with new cancer medicines approved by the Food and Drug Administration and European Medicines Agency: A retrospective cohort study. <i>European Journal of Cancer</i> , 2021, 155, 136-144.	1.3	20
9	646 PREDICTING RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH OESOPHAGEAL ADENOCARCINOMA. <i>Ecological Management and Restoration</i> , 2021, 34, .	0.2	0
10	Is there a role for physical activity when treating patients with cancer with immune checkpoint inhibitors? Protocol for a scoping review. <i>BMJ Open</i> , 2021, 11, e046052.	0.8	1
11	Predicting response to neoadjuvant chemotherapy in patients with oesophageal adenocarcinoma. <i>Acta Oncologica</i> , 2021, 60, 1629-1636.	0.8	2
12	P-OGC67 Gastric GISTs: Can presentation, Location and Radiological Features predict behaviour? â€œ Experience in a UK cohort. <i>British Journal of Surgery</i> , 2021, 108, .	0.1	0
13	Long-term adherence to GnRH agonists in men with prostate cancer. A nation-wide population-based study in prostate cancer data base Sweden. <i>Scandinavian Journal of Urology</i> , 2020, 54, 20-26.	0.6	11
14	Association of Serum Immunoglobulin Levels with Solid Cancer: A Systematic Review and Meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 527-538.	1.1	13
15	Associations between immune-suppressive and stimulating drugs and novel COVID-19â€”a systematic review of current evidence. <i>Ecancermedalscience</i> , 2020, 14, 1022.	0.6	360
16	Real-world insights into risk of developing cardiovascular disease following GnRH agonists versus antagonists for prostate cancer: a methodological protocol to a study using five European databases. <i>Fundamental and Clinical Pharmacology</i> , 2019, 33, 479-499.	1.0	3
17	Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer. <i>BMC Cancer</i> , 2017, 17, 494.	1.1	17
18	Confirmatory biopsy for the assessment of prostate cancer in men considering active surveillance: reference centre experience. <i>Ecancermedalscience</i> , 2016, 10, 633.	0.6	6